May 21, 2026 | Press Releases
SEATTLE, May 21, 2026 /PRNewswire/ — HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. The award recognizes HDT Bio’s MCDC...
Sep 22, 2025 | Press Releases
SEATTLE, Sept. 19, 2025 /PRNewswire/ — HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
Jan 24, 2025 | Press Releases
HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ — MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio’s proprietary self-amplifying replicon RNA...
Sep 17, 2024 | Press Releases
HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies,...
Aug 7, 2024 | Press Releases
Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...
Nov 16, 2023 | Press Releases
SEATTLE, Nov. 16, 2023 /PRNewswire/ — HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa...
